Venture valuations will rise significantly over the next 1-2 years, more than current levels.
“And so I do think we're gonna see a ongoing rise in valuations most likely over the next year or two, much more than we've seen today.”
→ Read the source episode
Our resolution criterion
disputableMedian or mean venture capital valuations for Series A-D rounds increase by >20% year-over-year in 2027 and/or 2028 compared to 2026 baseline.
More from No Priors: Artificial Intelligence | Technology | Startups
Renee Haas predicts that within 5+ years, chip design from idea to GDS2 file will be possible for certain designs, likely using AI tooling.
Max Hodak predicts that Cyens' in-house gene therapy will enter human trials within approximately one year
Renee Haas predicts that semiconductor supply chain constraints will persist for 3-5 years at minimum.
Max Hodak predicts that the next version of Prima will enter human trials within approximately one year and expand addressable patient population to millions
Max Hodak predicts that Cyens will make first commercial sales of Prima in Europe within weeks of July 2026
Brian Armstrong predicts New Limit will launch its first phase one clinical trial for epigenetic reprogramming in the next year (2027).
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.